

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION	as well	see Form PCT/ISA/220 as, where applicable, item 5 below.
18202 - 028WO1 International application No.	International filing date (day/month	/year)	(Earliest) Priority Date (day/month/year)
PCT/US2005/007867	11/03/2005		12/03/2004
Applicant			
LIGAND PHARMACEUTICALS INC	prepared by this International Searce	ching Autho	ority and is transmitted to the applicant
according to Article 18. A copy is being tra	insmitted to the International Bureau	•	
This International Search Report consists			
It is also accompanied by	a copy of each prior art document ci	ted in this r	report.
language in which it was filed, unl	ess otherwise indicated under this its search was carried out on the basis	em.	is of the international application in the ation of the international application furnished to
		disclosed	in the international application, see Box No. I.
2. Certain claims were fou	nd unsearchable (See Box II).		
3. Unity of invention is lac	king (see Box III).		
4. With regard to the title,			
X the text is approved as su	bmitted by the applicant.		
the text has been establis	hed by this Authority to read as follo	ws:	
	•		
5. With regard to the abstract,			
the text is approved as su	bmitted by the applicant.		
x the text has been establis	hed, according to Rule 38.2(b), by the	his Authori tional sear	ity as it appears in Box No. IV. The applicant ch report, submit comments to this Authority.
6. With regard to the drawings,			
a. the figure of the drawings to be p	ublished with the abstract is Figure	No	·
as suggested by t	•		•
as selected by thi	s Authority, because the applicant for	ailed to su	ggest a figure.
as selected by thi	s Authority, because this figure bett	er characte	erizes the invention.
b. none of the figures is to be	e published with the abstract.		





INTERNATIONAL SEARCH REPORT International application No. PCT/US2005/007867

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1,3-25,28,29,46-51 (all partially),61 (completely),58 62-82 (all partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1,3-25,28,29,46-51 (all partially), 61 (completely), 58,62-82 (all partially)

Compounds of general formula (I) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

2. claims: 1-25 (all partially), 26 and 27 (completely), 28 and 29 (partially), 30-38 (all completely), 46-51,58-82 (all partially)

Compounds of general formula (II) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

3. claims: 1,3-25,28,29,46-51,58 (all partially), 59 and 60 (completely), 62-82 (all partially)

Compounds of general formula (III) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

4. claims: 1-25,28,29 (all partially), 39-41 (completely), 46-58,62-82 (all partially)

Compounds of general formula (IV) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

5. claims: 1,3-25,28,29,42 (all partially), 43-45 (completely), 46-51,58,62-82 (all partially)

Compounds of general formula (V) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

6. claims: 1,3-25,28,29,42,46-51 (all partially), 52-57 (completely), 58,62-82 (all partially)

Compounds of general formula (VI) according to claim 1 as well as their pharmaceutical use and compositions according to claims 63-82

Provided herein are compounds

having a structure

selected from among Formula I, Formula II, Formula III, Formula IV, Formula V and Formula VI:

$$R^{3a}$$
 R^{6}
 R^{7}
 R^{8}
 R^{9}
 R^{1}
 R^{5}
 R^{4}
 R^{11}

(I)

$$\begin{array}{c|c}
R^{6a} & R^{7a} & R^{12} \\
R^{3} & & & & & & \\
R^{2} & & & & & & \\
R^{2} & & & & & & \\
R^{3} & & & & & & \\
R^{4} & & & & & & \\
R^{5} & & & & \\
R^{5} & & & & \\
R^{5} & & & & & \\
R^{5} & & & & & \\
R^{5} & & & \\
R^{$$

(II)

$$\begin{array}{c|cccc}
R^{19} & R^{20} & R^{22} \\
R^{18} & N & R^{23} \\
R^{21} & R^{26} & R^{25}
\end{array}$$
(V)

$$R^{19}$$
 R^{18}
 R^{20}
 R^{22}
 R^{23}
 R^{21}
 R^{25}
(VI)

that are androgen receptor modulators

and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.





International Application No PCT/US2005/007867

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
(DATABASE WPI Section Ch, Week 200424 Derwent Publications Ltd., London, GB; Class B02, AN 2004-257164 XP002331455 -& WO 2004/016576 A1 (TAKEDA CHEM IND LTD) 26 February 2004 (2004-02-26)	1-82	
(page 230; example 155 EP 1 122 242 A (YAMANOUCHI PHARMACEUTICAL CO. LTD) 8 August 2001 (2001-08-08) cited in the application page 39; compounds 1-33 page 1 claims 7,9	1-82	
	-/		

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
15 June 2005	0 5. 08. 2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Seitner, I





International Application No PCT/US2005/007867

0.00	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/032005	7,007,007
Category °	Citation of document, with indication, where appropriate, of the relevant passages	F	Relevant to claim No.
X	US 4 097 578 A (PERRONNET ET AL) 27 June 1978 (1978-06-27) cited in the application columns 1-2		1-82
x	WO 03/011824 A (BRISTOL-MYERS SQUIBB COMPANY; SUN, CHONGQING; ROBL, JEFFREY, A; SALVAT) 13 February 2003 (2003-02-13) cited in the application example 1 claims 7-11		1-82
P,X	WO 2005/000795 A (SMITHKLINE BEECHAM CORPORATION; BLANC, JEAN-BAPTISTE, E; CADILLA, RODO) 6 January 2005 (2005-01-06) examples 113,119,120,135 claims 37-42		1-82
X	ANLEZARK G M ET AL: "BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN E.COLI B NITROREDUCTASE" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 50, no. 5, January 1995 (1995-01), pages 609-618, XP000645552 ISSN: 0006-2952 example 1; table 2		1,61,73, 74,78,79
X	PANTHANANICKAL, AUGUSTINE ET AL: "Structure-activity relationship of aniline mustards acting against B-16 melanoma in mice" JOURNAL OF MEDICINAL CHEMISTRY, 22(10), 1267-9 CODEN: JMCMAR; ISSN: 0022-2623, 1979, XP002331449 table I; compound 7		1,61,73, 74,78,79
X	GRAVATT, G. LANCE ET AL: "DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol (Hoechst 33258)" JOURNAL OF MEDICINAL CHEMISTRY, 37(25), 4338-45 CODEN: JMCMAR; ISSN: 0022-2623, 1994, XP002331450 abstract examples 14,19		1,61
X	TURNBULL, KENNETH ET AL: "The reaction of 4-substituted aryl isocyanates with NaBH4/trifluoroacetic acid (TFA)" SYNTHESIS, (3), 391-392 CODEN: SYNTBF; ISSN: 0039-7881, 1999, XP008048153 scheme: compound 3e		1,61
	-/		





International Application No PCT/US2005/007867

		PC1/032003/00/66/
C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
X	NICULESCU-DUVAZ D ET AL: "Self-immolative nitrogen mustard prodrugs for suicide gene therapy" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 26, 17 December 1998 (1998-12-17), pages 5297-5309, XP002265049 ISSN: 0022-2623 compound 49 50	1,61
X ·	EP 0 711 768 A (MITSUI TOATSU CHEMICALS, INC; MITSUI CHEMICALS, INC) 15 May 1996 (1996-05-15) page 297, line 16 page 315, line 49 page 326, line 3 page 334, line 17 page 339, line 17	1,61
X	PALMER, BRIAN D. ET AL: "Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells" JOURNAL OF MEDICINAL CHEMISTRY, 35(17), 3214-22 CODEN: JMCMAR; ISSN: 0022-2623, 1992, XP002331451 table 1; compounds 7-10 11-14 examples 2,9,10,13,14	1,61,73, 74,78,79
X.	PALMER, B. D. ET AL: "Nitro analogs of chlorambucil as potential hypoxia-selective anti-tumor drugs" ANTI-CANCER DRUG DESIGN , 5(4), 337-49 CODEN: ACDDEA; ISSN: 0266-9536, 1990, XP008048139 table I; compound 3 6 8 examples 4,8,25	1,61
X	PALMER, BRIAN D. ET AL: "Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines" JOURNAL OF MEDICINAL CHEMISTRY, 33(1), 112-21 CODEN: JMCMAR; ISSN: 0022-2623, 1990, XP000609118 examples 5-7; table I	1,61,73, 74,78,79
	-/	





International Application No PCT/US2005/007867

	A DOCUMENTO CONCERNO TO SECURIO DE LA CONCENNA DEL CONCENNA DEL CONCENNA DE LA CO	PC1/032003/00/86/
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS,	1,61
	OHIO, US; PRASMICKIENE, G. ET AL: "Synthesis and study of the reactivity of p-[bis(2-chloropropyl)amino]phenylalkanoic acids" XP002331454 retrieved from STN	
	Database accession no. 1969:430178 CAS RN: 23004-87-7 abstract	
	& IZVESTIYA AKADEMII NAUK SSSR, SERIYA KHIMICHESKAYA , (3), 643-6 CODEN: IASKA6; ISSN: 0002-3353, 1969,	
X	POPP, FRANK D.: "Synthesis of potential anticancer agents. X. Preparation and reactions of aldehydes related to benzaldehyde mustard" JOURNAL OF MEDICINAL CHEMISTRY , 7(2), 210-12 CODEN: JMCMAR; ISSN: 0022-2623, 1964, XP002331453 page 212, column 1 example IX	1,61,73, 74,78,79
X	STEINMAN, MARTIN ET AL: "1-Poly(fluoroalkyl)benzodiazepines" JOURNAL OF MEDICINAL CHEMISTRY, 16(12), 1354-60 CODEN: JMCMAR; ISSN: 0022-2623, 1973, XP002295070 example 12; table I example 17; table II	1,61
X	ABELA MEDICI, ANTHONY J. ET AL: "Cytotoxic compounds. Part 21. Chloro-, methoxy-, and methoxycarbonyl-derivatives of (bis-2-chloroethylamino)-phenols and anilines" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999), (20), 2258-63 CODEN: JCPRB4; ISSN: 0300-922X, 1977, XP008048335 example 10	1,61,73, 74,78,79
X	US 4 202 895 A (INABA, SHIGEHO ET AL) 13 May 1980 (1980-05-13) column 9, line 62 - line 63	1,61
Α	WO 02/16310 A (GTX, INC; DALTON, JAMES; MILLER, DUANE, D; YIN, DONGHUA; HE, YALI) 28 February 2002 (2002-02-28) claim 1 examples 1,2	1,61, 63-82
٠.	-/	





International Application No PCT/US2005/007867

		DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
A	WO 98/22432 A (YAMANOUCHI PHARMACEUTICAL CO., LTD; TANIGUCHI, NOBUAKI; OKADA, MINORU;) 28 May 1998 (1998-05-28) abstract page 33 - page 48		1,61, 63-82		
			·		
			:		



Information on patent family members

International Application No
PCT/US2005/007867

		PC1/052005/00/86/					
	ent document in search report		Publication date		Patent family member(s)		Publication date
 WO	2004016576	A1	26-02-2004	AU BR CA	2003254993 0313405 2495383	Α	03-03-2004 12-07-2005 26-02-2004
				EP JP	1553074 2004091486		13-07-2005 25-03-2004
	1122242	Α	08-08-2001	AU	754529		21-11-2002
Lr	1122242	n	00 00 2001	ΑU	5654499	Α .	10-04-2000
				BR CA	9914018 2345146		03-07-2001 30-03-2000
				EP	1122242	A1	08-08-2001
			•	JP US	3390744 2004010037		31-03-2003 15-01-2004
			•	US	6673799	B1 ·	06-01-2004
		•	•	CN WO	1129581 0017163		03-12-2003 30-03-2000
				JP	2003137873	Α	14-05-2003
		•		PL RU	346795 2221785		25-02-2002 20-01-2004
US	4097578	Α	27-06-1978	FR AU	2329276 500542		27-05-1977 24-05-1979
				ΑU	1909576	Α	04-05-1978
				BE BG	847742 60533		28-04-1977 28-07-1995
	,			CA	1086751	A1	30-09-1980
				CH DE	599164 2649925		12-05-1978 12-05-1977
				DK	487476	A ,B,	30-04-1977
				ES GB	452746 1518444		01-10-1977 19-07-1978
				ΙE	43875	B1	17-06-1981
				JP JP	1289956 52057176		14-11-1985 11-05-1977
	•			JP	60011701	В	27-03-1985
			÷	LU LU	76085 88282		31-05-1977 04-05-1994
				MD	246	B1	31-07-1995
				NL NL	930079 7611576		16-09-1993 03-05-1977
				SE	430502	В	21-11-1983
				SE Su	7610859 596165		30-04-1977 28-02-1978
 WO	03011824	 A	13-02-2003	EP	1414795	A1	06-05-2004
,,,		••	20 02 2000	WO	03011824	A1	13-02-2003
				US US	2003055094 2004092559		20-03-2003 13-05-2004
WO	2005000795	Α	06-01-2005	WO	2005000795		06-01-2005
ΕP	0711768	Α	15-05-1996	CA	2168016		07-12-1995
				DE DE	69525418 69525418		21-03-2002 17-10-2002
				EP	0711768		15-05-1996
				EP US ES	0711768 5852011 2172585	. A	15-05-1996 22-12-1998 01-10-2002





Information on patent family members

International Application No PCT/US2005/007867

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0711768	Α	· · · · · · · · · · · · · · · · · · ·	JP	3258531	B2	18-02-2002
			JР	9003065	Α	07-01-1997
			KR	172649	B1	01-02-1999
US 4202895	Α	13-05-1980	NONE			
WO 0216310	Α	28-02-2002	AU	8523001	Α	04-03-2002
			BR	0114801	Α	14-10-2003
			CA	2420279	A1	28-02-2002
			CN	1471508	Α	28-01-2004
			EP	1401801	A1	31-03-2004
			EP	1491524	A2	29-12-2004
.*		•	JP	2004518617	Τ.	24-06-2004
		,	WO	0216310	A1	28-02-2002
			US		A1	25-07-2002
			US		A1	25-07-2002
•			US	2002173495		21-11-2002
			US	2003022868		30-01-2003
			US	2003162761		28-08-2003
	•		US	2003232792		18-12-2003
			US	2003225040	A1	04-12-2003
		•	US	2004014975		22-01-2004
			US	2004260108		23-12-2004
			US	2005038110	Al	17-02-2005
WO 9822432	Α	28-05-1998	ΑU	4966497	Α	10-06-1998
			WO	9822432	A1	28-05-1998